Genomic Biomarker Market by Product (Consumables, Services, Software), Type (Predictive Biomarkers, Prognostic Biomarkers), Disease Indication, End-User - Global Forecast 2024-2030

Genomic Biomarker Market by Product (Consumables, Services, Software), Type (Predictive Biomarkers, Prognostic Biomarkers), Disease Indication, End-User - Global Forecast 2024-2030

The Genomic Biomarker Market size was estimated at USD 4.40 billion in 2023 and expected to reach USD 4.67 billion in 2024, at a CAGR 6.67% to reach USD 6.92 billion by 2030.

Genomic biomarkers are DNA or RNA molecules that are used to examine the complex relationships between genetics and the environment and significantly enhance understanding and management of health, diseases, and agricultural outputs. These biomarkers play a pivotal role in early disease diagnosis and risk assessment, facilitating the identification of potential health issues such as cancer and cardiovascular diseases before they manifest symptoms. Genomic biomarkers offer personalized medicine and enable the customization of treatments to each individual's genetic profile, optimizing therapy effectiveness and minimizing adverse effects. The pharmaceutical sector benefits immensely from genomic biomarkers in the development of targeted medications that specifically address the molecular basis of diseases. In agriculture, they enable the breeding of crop varieties with enhanced yields and resistance to environmental stresses. Genomic biomarkers are widely used in agricultural research, healthcare, and farming practices. The growing applications of genomic markers for personalized medicine are surging the need for genomic biomarkers in the healthcare and pharmaceutical sectors. Additionally, the growing regulatory support by the governments for research and development of genomic biomarkers is driving the demand for advanced and more effective genomic biomarkers. However, technical limitations associated with the development of these biomarkers hinder the demand. Moreover, the integration of machine learning and AI with genomic studies enhances the predictive ability of genomic biomarkers.

Regional Insights



In the Americas, particularly North America, is exhibiting a robust demand for genomic biomarkers with the well-established healthcare infrastructure and a significant increase in investments in biomedical research. With a high prevalence of chronic diseases such as cancer and cardiovascular diseases within the region, personalized medicine approaches are thus increasing the application of genomic biomarkers. Moreover, ongoing collaborations between research institutes and biotechnology companies enhance the innovation of genomic biomarkers, support government policies on genomics research funds, and regulate advancements to expand the demand within the region. This region is experiencing rapid growth in the genomic biomarker market with the surging expansion of the healthcare and diagnostic sectors. Countries such as China, Japan, and South Korea have robust needs for genomic biomarkers due to their fast-growing biotech sectors. Rising healthcare expenditure, rising awareness about personalized medicine, and an increase in public and private investment in genomic research are important drivers. Europe and the Middle East regions show rapid growth driven by advanced healthcare systems and widespread adoption of next-generation sequencing technologies. Government funding in genomics and collaborations across countries in the European Union are significantly growing the adoption of genomic biomarkers. There is potential growth in the African region due to an increasing focus on improving healthcare systems and rising foreign investments in the healthcare sector.

Market Insights



Market Dynamics



The market dynamics represent an ever-changing landscape of the Genomic Biomarker Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers


Increasing usage of genomic biomarkers in early detection and diagnosis of chronic disease
Governments and regulatory support for genomic biomarker research
Growing applications of genomic biomarkers in personalized medicine

Market Restraints


High cost and technical issues associated with developing genomic biomarkers

Market Opportunities


Integration of AI and machine learning with genomic studies
Growing interest in developing advanced noninvasive genomic biomarkers

Market Challenges


Ethical and legal concerns regarding the use of genomic biomarkers

Market Segmentation Analysis


Type: Proliferating use of prognostic biomarkers in pharmaceutical research
End-user: Expanding application of genomic biomarkers in diagnostic centers

Market Disruption Analysis


Porter’s Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix



The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Genomic Biomarker Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis



The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Genomic Biomarker Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments




Bio-Rad Introduces Revolutionary Multiplexed Digital PCR Assay for Enhanced Breast Cancer Research

Bio-Rad Laboratories, Inc. unveiled its groundbreaking ddPLEX ESR1 Mutation Detection Kit. his kit marks a significant advance in the oncology sector by offering an ultrasensitive, multiplexed digital PCR assay designed to detect, differentiate, and quantitatively assess seven critical ESR1 mutations from a single sample. This development expands Bio-Rad’s portfolio in digital PCR solutions and strengthens its commitment to supporting oncology researchers in biomarker discovery and clinical trials, thereby improving patient care continuity and treatment efficacy.


Biofidelity's Introduction ASPYRE-Lung RUO Reagents for Enhanced and Rapid Genomic Biomarker Analysis

Biofidelity unveiled the ASPYRE-Lung RUO, a cutting-edge reagent product designed to simplify and expedite the detection of genomic biomarkers in labs globally. The ASPYRE-Lung technology uses standard PCR instruments already present in most laboratories, eliminating the need for specialized staff or complex setups. Its high sensitivity facilitates the use of tissue samples with minimal tumor content, considerably lowering the threshold compared to traditional assays. The ASPYRE-Lung RUO is poised to revolutionize diagnostic tests, ensuring high-quality results with quick turnarounds for diverse research applications.


Illumina's Breakthrough in Oncology TruSight Oncology 500 ctDNA v2 Enhances Solid Tumor Genomic Profiling

Illumina Inc. introduced the latest version of its liquid biopsy assay, the TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2). This cutting-edge research tool offers noninvasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA), providing critical data when traditional tissue sample testing is not feasible. As Illumina gears up to integrate automation in their assays, this innovation stands poised to redefine the landscape of tumor profiling, rendering it an increasingly indispensable tool in precision oncology.

Strategy Analysis & Recommendation



The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Genomic Biomarker Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles



The report delves into recent significant developments in the Genomic Biomarker Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., APIS Assay Technologies Limited, Augurex Life Sciences Corp, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Biocrates Life Sciences AG, Biostarks Laboratories SA, Bruker Corporation, CD Genomics, Charles River Laboratories, Inc., DH Life Sciences, LLC., Elo Health, Inc., Eurofins Scientific corporation, F. Hoffmann-La Roche Ltd, Illumina Inc., Merck KGaA, Myriad Genetics, Inc, Owkin, Inc, and Thermo Fisher Scientific company.

Market Segmentation & Coverage



This research report categorizes the Genomic Biomarker Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
Consumables
Services
Software
Type
Predictive Biomarkers
Prognostic Biomarkers
Disease Indication
Cardiovascular Diseases
Neurological Diseases
Oncology
Renal Disorders
End-User
Diagnostic Centers
Hospitals
Research Institutions
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

Please Note: PDF & Excel + Online Access - 1 Year